Machine Learning Scientist II/Sr (Biomedical Images) - UK

United Kingdom

Apply with AI Apply

Not SpecifiedCompensation

Junior (1 to 2 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, Biomedical EngineeringIndustries

Requirements

Candidates should possess a PhD with 3+ years of industry experience in Computer Vision, Machine Learning, Biomedical Engineering, or a related field, or an MS with 5+ years of experience. They must have solid experience with deep learning for images, including self-supervised pre-training, Vision Transformers, or vector quantization methods, and hands-on work with large medical or scientific imaging datasets. Proficiency in PyTorch or JAX and experience running distributed training on GPUs or cloud HPC resources are also required, along with strong software engineering habits.

Responsibilities

The Machine Learning Scientist II/Sr will evaluate, adapt, and integrate pretrained computer-vision models into Enchant’s existing modalities, locate and curate clinical imaging datasets, build reliable data pipelines for large image collections, convert research prototypes into production services, collaborate with discovery, pre-clinical, and clinical teams to translate image insights, and share results through code, documentation, and internal presentations while mentoring colleagues in vision and multimodal ML.

Skills

Deep Learning

Computer Vision

Vision Transformers

Vector Quantization

PyTorch

JAX

Distributed GPU Training

Medical Imaging

Data Pipelines

Model Deployment

Multimodal ML

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters

2012Year Founded

$430.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees